J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Trump Buys SpaceX Shares After Record IPO 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Add as a preferred source on Google
CAMBRIDGE, Mass., April 27, 2018 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations from its Investor Day, including first quarter financial results, on Friday, May 4, 2018 at 8:00 a.m. ET in New York.
Presentations will be given by members of Agios' leadership team and external speakers including:
- David Schenkein, M.D., Chief Executive Officer
- Scott Biller, Ph.D., Chief Scientific Officer
- Chris Bowden, M.D., Chief Medical Officer
- Andrew Hirsch, Chief Financial Officer and Head of Corporate Development
- Steve Hoerter, Chief Commercial Officer
- Darrin Miles, Vice President, IDH Program Management
- Susan Pandya, M.D., Senior Medical Director, Clinical Development
- Kevin Marks, Ph.D., Senior Director, Head of Cancer Biology
- Maeve Lowery, M.B., B.Ch., B.A.O, Trinity College Dublin
A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The presentations are scheduled to begin at 8:00 a.m. ET and conclude at 12:00 p.m. ET. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Investors:
Renee Leck, 617-649-8299
Senior Manager, Investor Relations
[email protected]
Media:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
[email protected]
